Baxter launches swine flu vaccine

Celvapan is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Celvapan should be used in accordance with official guidance. The dose recommendations are based on safety and immunogenicity data available from the administration of a vaccine containing 7.5 microgram HA derived from A/Vietnam/1203/2004 (H5N1) in adults, including the elderly. Doses were given on days 0 and 21.

The decision to use Celvapan in each age group should take into account the extent of the clinical data available with the version containing H5N1 antigen and the disease characteristics of the current influenza pandemic.

View Celvapan drug record

Further information: Baxter

To sign up for the MIMS monthly news update, register at

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more